Adventrx submits ANX-530 NDA, raises $19M

Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) submitted an NDA to FDA for ANX-530 to treat non-small cell lung cancer (NSCLC). The NDA was submitted under section 505(b)(2) of the Food, Drug and Cosmetic Act, which allows sponsors to reference data on safety and efficacy from the scientific literature or from previously approved products. ANX-530 is an emulsion formulation of vinorelbine tartrate. ...